Colorectal Cancer

Overwhelming evidence supports a chemopreventive benefit of aspirin on colo­rectal cancer (CRC), and a potential effect on other cancers and cardiovascular risk. Read More ›

Results of a phase 3 study of an investigational monoclonal antibody, MABp1 (Xilonix; XBiotech), evaluated for cachexia in metastatic colorectal cancer (CRC), revealed a surprising finding: patients in the experimental arm showed a trend toward increased overall survival (an end point difficult to reach in any treatment-refractory cancer), with pharmacodynamics activity consistent with this result, investigators reported at the 2015 Gastrointestinal Cancers Symposium, held in San Francisco, California. Read More ›

The US Food and Drug Administration (FDA) approved ziv-aflibercept injection (Zaltrap, Sanofi US, Inc.) for use in combination with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. Read More ›

The clinical response to regorafenib does not depend on tumor mutations. Among patients with metastatic colorectal cancer who participated in the phase 3 CORRECT (Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy) study, an analysis of tumor specimens for KRAS and PIK3CA mutations did not predict clinical benefit in the patients assigned to regorafenib compared with placebo, said Michael Jeffers, PhD. Read More ›

In recent years, researchers have considered a potential link between beta-blockers and a decreased risk of cancer. This theory stems from the fact that beta-blockers inhibit the actions of the stress hormone norepinephrine. This, along with studies that found norepinephrine can promote the growth and spread of cancer cells, led researchers to reason that the beta-blockers could have anticancer properties.

However, a recent study published early online in Cancer revealed that the use of beta-blockers showed no reduction of colorectal cancer risk.

Read More ›

Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC), is the most common cause of hereditary endometrial cancer. It accounts for at least 2% to 3% of all endometrial cancer cases and 9% to 10% of endometrial cancer cases in women diagnosed younger than 50 years of age.1-3 Women with Lynch syndrome have a high lifetime risk for colorectal (30%- 52%)4 and endometrial (20%-71%)5 cancer. Read More ›

For patients with colorectal cancer (CRC), advances in molecular profiling have led to an explosion in novel agents specific for targets above and beyond the epidermal growth factor receptor (EGFR). Joseph Tabernero, MD, director of clinical research at Vall d’Hebron Institute of Oncology in Barcelona, Spain, previewed the future of treatment for CRC.

Read More ›

SAN DIEGO—Two studies presented at the 52nd annual meeting of the American Society for Radiation Oncology have found that the use of fast neutron radiotherapy (FNRT), a form of radiation that is about three times more powerful than typical photon radiotherapy, is highly effective and safe for patients with non–small-cell lung cancer (NSCLC).

Read More ›

Colorectal cancer (CRC) is the third most common cancer worldwide, and the fourth most common cause of death from cancer.1,2 It is estimated that in 2009, 146,970 men and women will have been diagnosed with cancer of the colon and rectum in the United States, and that 49,920 will have died from the disease.3 From 2002 to 2006 the median age of diagnosis was 71 years.3

Read More ›

Page 2 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: